464 related articles for article (PubMed ID: 20395065)
1. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
Dósa E; Guillaume DJ; Haluska M; Lacy CA; Hamilton BE; Njus JM; Rooney WD; Kraemer DF; Muldoon LL; Neuwelt EA
Neuro Oncol; 2011 Feb; 13(2):251-60. PubMed ID: 21163809
[TBL] [Abstract][Full Text] [Related]
4. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
Thompson EM; Guillaume DJ; Dósa E; Li X; Nazemi KJ; Gahramanov S; Hamilton BE; Neuwelt EA
J Neurooncol; 2012 Aug; 109(1):105-14. PubMed ID: 22528798
[TBL] [Abstract][Full Text] [Related]
5. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
[TBL] [Abstract][Full Text] [Related]
7. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
Gahramanov S; Muldoon LL; Li X; Neuwelt EA
Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
9. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
10. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.
Varallyay CG; Nesbit E; Fu R; Gahramanov S; Moloney B; Earl E; Muldoon LL; Li X; Rooney WD; Neuwelt EA
J Cereb Blood Flow Metab; 2013 May; 33(5):780-6. PubMed ID: 23486297
[TBL] [Abstract][Full Text] [Related]
11. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
[TBL] [Abstract][Full Text] [Related]
12. Quantitative comparison of delayed ferumoxytol T
Horváth A; Varallyay CG; Schwartz D; Toth GB; Netto JP; Barajas R; Várallyay P; Szidonya L; Firkins J; Youngers E; Fu R; Ambady P; Bogner P; Neuwelt EA
Magn Reson Med; 2018 Jul; 80(1):224-230. PubMed ID: 29205477
[TBL] [Abstract][Full Text] [Related]
13. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
14. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
[TBL] [Abstract][Full Text] [Related]
15. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study.
Steidl E; Müller M; Müller A; Herrlinger U; Hattingen E
J Neurooncol; 2019 Sep; 144(2):409-417. PubMed ID: 31321614
[TBL] [Abstract][Full Text] [Related]
19. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]